A Phase I, Open-Label, Multi-Center, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 Administered Weekly in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2012
At a glance
- Drugs Codrituzumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 16 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.